Hospital
Baystate Wing Hospital Corporation
Baystate Wing Hospital Corporation was paid $38.22M by Medicaid between Jan 2018 and Dec 2024, across 273 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoBAYSTATE WING HOSPITAL CORPORATION
PALMER, MA 01069
PALMER, MA 01069
33aNPI1962410233assigned 08/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.22M
24GClaims935,684
24DCodes billed273
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#28 of 66
Median peer was paid$29.11M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 158,469 | $6.17M | |
| 2019 | 137,271 | $4.79M | |
| 2020 | 121,235 | $4.10M | |
| 2021 | 133,810 | $4.73M | |
| 2022 | 155,248 | $6.65M | |
| 2023 | 141,955 | $6.66M | |
| 2024incomplete | 87,696 | $5.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 58,742 | 50,808 | $6.36M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 45,815 | 40,259 | $5.23M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 12% | 29,402 | 26,073 | $4.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 30,936 | 26,582 | $4.09M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 13,047 | 10,541 | $3.83M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6.1% | 15,522 | 14,059 | $2.33M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.1% | 30,756 | 24,646 | $814K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 14,537 | 4,852 | $801K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 6,255 | 5,854 | $768K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 5,858 | 5,468 | $570K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 5,720 | 5,412 | $546K |
| S9485 | Crisis intervention mental health services, per diem | 1.1% | 1,093 | 677 | $427K |
261 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 2,894 | $416K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 4,700 | $414K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 8,231 | $375K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,323 | $360K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 9,252 | $349K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,409 | $259K |
| 90837 | Psychotherapy session, about an hour | <1% | 3,705 | $252K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,268 | $225K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,838 | $210K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,352 | $210K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,815 | $196K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,705 | $194K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,765 | $191K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,411 | $178K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 148 | $177K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,516 | $157K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,289 | $146K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 965 | $135K |
| 87631 | <1% | 1,795 | $128K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 742 | $126K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,359 | $123K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,192 | $121K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,835 | $113K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,002 | $107K |
| 97161 | <1% | 1,655 | $105K | |
| G0378 | Hospital observation service, per hour | <1% | 2,666 | $103K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,685 | $85K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 92 | $84K |
| 83880 | <1% | 5,360 | $78K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,036 | $76K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 930 | $72K |
| 84484 | <1% | 11,360 | $70K | |
| 93971 | <1% | 772 | $69K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,085 | $68K |
| 20610 | <1% | 550 | $63K | |
| 80053 | Comprehensive metabolic panel | <1% | 16,999 | $62K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,003 | $60K |
| 83605 | <1% | 9,066 | $60K | |
| 83690 | <1% | 13,412 | $56K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,993 | $51K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,322 | $48K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 443 | $47K |
| 81025 | <1% | 8,216 | $45K | |
| Q3014 | Telehealth originating site facility fee | <1% | 12,954 | $43K |
| 12001 | <1% | 306 | $39K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,491 | $37K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 263 | $37K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,463 | $36K |
| 76830 | Ultrasound, transvaginal | <1% | 321 | $35K |
| ATP14 | <1% | 4,535 | $34K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,358 | $34K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,550 | $33K |
| 83735 | <1% | 8,791 | $30K | |
| 87040 | <1% | 5,155 | $30K | |
| 85027 | <1% | 8,923 | $29K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,321 | $28K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 349 | $28K |
| 73630 | <1% | 2,804 | $27K | |
| ATP08 | <1% | 4,428 | $27K | |
| 81001 | <1% | 14,508 | $27K | |
| 73562 | <1% | 1,943 | $25K | |
| 87088 | <1% | 3,837 | $25K | |
| 73030 | <1% | 2,023 | $25K | |
| 90715 | <1% | 853 | $24K | |
| 73610 | <1% | 2,542 | $24K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 234 | $23K |
| 73130 | <1% | 1,819 | $22K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 135 | $22K |
| 80051 | <1% | 17,345 | $21K | |
| ATP07 | <1% | 3,193 | $21K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 155 | $21K |
| 97162 | <1% | 437 | $20K | |
| 72100 | <1% | 1,112 | $20K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,552 | $18K |
| 90686 | <1% | 1,079 | $17K | |
| 87081 | <1% | 3,131 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,246 | $16K |
| ATP11 | <1% | 2,334 | $16K | |
| 80061 | Lipid panel | <1% | 6,879 | $15K |
| 73110 | <1% | 922 | $15K | |
| 73502 | <1% | 755 | $14K | |
| 84703 | <1% | 2,477 | $13K | |
| 86140 | <1% | 4,202 | $13K | |
| 93975 | <1% | 109 | $13K | |
| 82565 | <1% | 18,724 | $12K | |
| 70496 | <1% | 79 | $12K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 81 | $12K |
| 85379 | <1% | 2,024 | $12K | |
| 71250 | <1% | 335 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 277 | $12K |
| 84439 | <1% | 2,415 | $11K | |
| 81003 | <1% | 8,197 | $11K | |
| 85610 | <1% | 7,426 | $11K | |
| 86803 | <1% | 1,247 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 297 | $10K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,469 | $10K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 580 | $10K |
| 82947 | <1% | 14,758 | $10K | |
| 82607 | <1% | 1,422 | $10K | |
| 84702 | <1% | 843 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 424 | $9K |
| 84520 | <1% | 16,776 | $9K | |
| ATP17 | <1% | 1,325 | $8K | |
| 80305 | <1% | 1,335 | $8K | |
| 87186 | <1% | 1,884 | $8K | |
| 10060 | <1% | 60 | $8K | |
| 82728 | <1% | 1,225 | $8K | |
| 90674 | <1% | 402 | $7K | |
| 80076 | <1% | 4,404 | $7K | |
| 84460 | <1% | 9,240 | $6K | |
| 71271 | <1% | 192 | $6K | |
| 84450 | <1% | 9,019 | $5K | |
| 77080 | <1% | 171 | $5K | |
| 87070 | <1% | 837 | $5K | |
| J3490 | Unclassified drugs | <1% | 1,062 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,208 | $5K |
| 83550 | <1% | 1,288 | $5K | |
| 92587 | <1% | 77 | $4K | |
| 84075 | <1% | 7,566 | $4K | |
| 12002 | <1% | 43 | $4K | |
| 82247 | <1% | 7,417 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,506 | $4K |
| 83540 | <1% | 1,417 | $4K | |
| ATP15 | <1% | 585 | $4K | |
| 76642 | <1% | 28 | $4K | |
| ATP12 | <1% | 552 | $4K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 28 | $3K |
| 12011 | <1% | 13 | $3K | |
| 92567 | <1% | 287 | $3K | |
| ATP10 | <1% | 486 | $3K | |
| 76775 | <1% | 46 | $3K | |
| 87147 | <1% | 762 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,267 | $3K |
| 94664 | <1% | 918 | $3K | |
| 87476 | <1% | 113 | $3K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 67 | $3K |
| 85730 | <1% | 847 | $2K | |
| 82570 | <1% | 1,107 | $2K | |
| V5266 | Battery for use in hearing device | <1% | 56 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,676 | $2K |
| 87486 | <1% | 156 | $2K | |
| 87581 | <1% | 156 | $2K | |
| 87077 | <1% | 1,181 | $2K | |
| 94060 | <1% | 12 | $2K | |
| 82746 | <1% | 280 | $2K | |
| 85652 | <1% | 1,325 | $2K | |
| 73560 | <1% | 276 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,487 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,790 | $2K |
| 84153 | <1% | 190 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,376 | $2K |
| 73140 | <1% | 134 | $2K | |
| ATP03 | <1% | 1,348 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 76 | $2K |
| 80050 | General health panel | <1% | 61 | $2K |
| 94729 | <1% | 38 | $2K | |
| 82043 | <1% | 834 | $2K | |
| 73080 | <1% | 71 | $2K | |
| 69210 | <1% | 121 | $1K | |
| 86618 | <1% | 143 | $1K | |
| 83655 | <1% | 110 | $1K | |
| 86780 | <1% | 124 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,144 | $1K |
| 82962 | <1% | 6,192 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 732 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $1K |
| 93225 | <1% | 27 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 43 | $1K |
| 82550 | <1% | 1,226 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,288 | $1K |
| 29125 | <1% | 35 | $1K | |
| 77062 | <1% | 12 | $1K | |
| 98940 | <1% | 247 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 34 | $1K |
| 87210 | <1% | 301 | $994.66 | |
| 94726 | <1% | 12 | $976.14 | |
| 93017 | <1% | 13 | $889.56 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,054 | $823.32 |
| 87205 | <1% | 347 | $779.46 | |
| 92579 | <1% | 26 | $769.34 | |
| 76937 | <1% | 111 | $763.14 | |
| 87340 | <1% | 95 | $762.85 | |
| 87660 | <1% | 41 | $682.44 | |
| 87510 | <1% | 41 | $682.44 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,570 | $681.82 |
| 87480 | <1% | 40 | $661.76 | |
| 94727 | <1% | 24 | $627.00 | |
| 96376 | <1% | 4,244 | $624.64 | |
| 74018 | <1% | 44 | $601.08 | |
| ATP09 | <1% | 106 | $582.40 | |
| 93226 | <1% | 27 | $547.47 | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $514.68 |
| 83718 | <1% | 135 | $504.78 | |
| 86850 | <1% | 60 | $494.65 | |
| ATP18 | <1% | 101 | $460.74 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 19 | $435.04 |
| ATP06 | <1% | 83 | $420.16 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $397.53 |
| 93296 | <1% | 25 | $356.09 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 34 | $344.60 |
| 82274 | <1% | 60 | $302.68 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,601 | $288.83 |
| 90732 | <1% | 27 | $274.86 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $264.70 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,877 | $257.41 |
| 90662 | <1% | 246 | $244.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,582 | $242.76 |
| 70486 | <1% | 12 | $228.63 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 23 | $224.07 |
| 82465 | <1% | 190 | $209.54 | |
| 36410 | <1% | 50 | $204.12 | |
| 73590 | <1% | 25 | $199.11 | |
| 80179 | <1% | 78 | $197.28 | |
| 70498 | <1% | 65 | $192.61 | |
| ATP02 | <1% | 80 | $187.95 | |
| 86200 | <1% | 13 | $148.46 | |
| 86900 | <1% | 86 | $128.92 | |
| 86901 | <1% | 86 | $128.92 | |
| 84100 | <1% | 272 | $124.08 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 19 | $112.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 150 | $100.07 |
| 80164 | <1% | 14 | $97.86 | |
| 11056 | <1% | 14 | $96.88 | |
| 0004A | <1% | 19 | $91.74 | |
| 11719 | <1% | 51 | $81.59 | |
| ATP13 | <1% | 14 | $78.65 | |
| 81002 | <1% | 67 | $76.56 | |
| 84481 | <1% | 12 | $69.88 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 60 | $42.38 |
| 82310 | <1% | 374 | $38.60 | |
| 84550 | <1% | 86 | $28.09 | |
| 84155 | <1% | 130 | $19.88 | |
| 84156 | <1% | 29 | $18.85 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 13 | $17.22 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 52 | $17.13 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 318 | $14.35 |
| 82040 | <1% | 152 | $8.57 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 237 | $1.38 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 418 | $1.22 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 352 | $0.00 |
| 92015 | Determination of refractive state | 0% | 16 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 122 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 163 | $0.00 |
| 96367 | 0% | 12 | $0.00 | |
| 80143 | 0% | 97 | $0.00 | |
| 90670 | 0% | 40 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 96 | $0.00 |
| 82248 | 0% | 51 | $0.00 | |
| 87469 | 0% | 33 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 27 | $0.00 |
| 93356 | 0% | 14 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 126 | $0.00 |
| 90688 | 0% | 25 | $0.00 | |
| 36416 | 0% | 249 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 66 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 25 | $0.00 |
| 87478 | 0% | 33 | $0.00 | |
| 87468 | 0% | 33 | $0.00 | |
| 88304 | 0% | 31 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 25 | $0.00 |
| 90839 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCARTHY, RAYMOND (SR. VP, CFO & TREASURER, BH)
| Provider | Location | Paid |
|---|---|---|
| Baystate Medical Center INC | Springfield, MA | $40.55M |
| Baystate Franklin Medical Center | Greenfield, MA | $29.11M |
| Baystate Wing Hospital Corporation | Palmer, MA | $2.29M |
| Baystate Medical Center INC | Springfield, MA | $1.12M |
| Baystate Franklin Medical Center | Greenfield, MA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.